ADMA Biologics, Inc.

ADMA Biologics, Inc.verified

ADMA

Price:

$9.56

Market Cap:

$2.22B

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and pre...[Read more]

Industry

Biotechnology

IPO Date

2013-10-17

Stock Exchange

NASDAQ

Ticker

ADMA

The PE Ratio as of May 2024 (TTM) for ADMA Biologics, Inc. (ADMA) is -478.00

According to ADMA Biologics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -478.00. This represents a change of -3714.17% compared to the average of 13.23 of the last 4 quarters.

ADMA Biologics, Inc. (ADMA) Historical PE Ratio (quarterly & annually)

How has ADMA PE Ratio performed in the past?

The mean historical PE Ratio of ADMA Biologics, Inc. over the last ten years is -7.03. The current -478.00 PE Ratio has changed 680.02% with respect to the historical average. Over the past ten years (40 quarters), ADMA's PE Ratio was at its highest in in the September 2023 quarter at 78.60. The PE Ratio was at its lowest in in the June 2023 quarter at -32.25.

Quarterly (TTM)
Annual

Average

-7.03

Median

-3.50

Minimum

-35.85

Maximum

-1.64

ADMA Biologics, Inc. (ADMA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of ADMA Biologics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 297.76%

Maximum Annual PE Ratio = -1.64

Minimum Annual Increase = -49.68%

Minimum Annual PE Ratio = -35.85

Quarterly (TTM)
Annual
YearPE RatioChange
2023-35.85297.76%
2022-9.01286.76%
2021-2.3321.53%
2020-1.92-49.68%
2019-3.81131.98%
2018-1.64-2.19%
2017-1.68-47.33%
2016-3.19-31.81%
2015-4.68-24.25%
2014-6.1788.16%

ADMA Biologics, Inc. (ADMA) Average PE Ratio

How has ADMA PE Ratio performed in the past?

The current PE Ratio of ADMA Biologics, Inc. (ADMA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-15.73

5-year avg

-10.58

10-year avg

-7.03

ADMA Biologics, Inc. (ADMA) PE Ratio vs. Peers

How is ADMA’s PE Ratio compared to its peers?

ADMA Biologics, Inc.’s PE Ratio is less than Atara Biotherapeutics, Inc. (-0.38), less than Fate Therapeutics, Inc. (-1.87), less than Sana Biotechnology, Inc. (-5.65), less than Caribou Biosciences, Inc. (-2.30), less than Arcus Biosciences, Inc. (-6.02), less than TFF Pharmaceuticals, Inc. (-0.26), less than INmune Bio, Inc. (-5.28), less than Anebulo Pharmaceuticals, Inc. (-5.87), less than Abcam plc (15.89K), less than AN2 Therapeutics, Inc. (-0.91), less than 89bio, Inc. (-4.73), less than Madrigal Pharmaceuticals, Inc. (-10.34), less than Pliant Therapeutics, Inc. (-4.49), less than Arcellx, Inc. (-54.17), less than Stoke Therapeutics, Inc. (-6.14), less than Protalix BioTherapeutics, Inc. (13.12), less than Cidara Therapeutics, Inc. (-1.50), less than Akebia Therapeutics, Inc. (-5.24), less than X4 Pharmaceuticals, Inc. (-1.40), less than Seres Therapeutics, Inc. (-1.62), less than Vaxart, Inc. (-1.79), less than iBio, Inc. (-0.35), less than Tonix Pharmaceuticals Holding Corp. (-0.14), less than BioCryst Pharmaceuticals, Inc. (-6.06),

Build a custom stock screener for ADMA Biologics, Inc. (ADMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ADMA Biologics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ADMA Biologics, Inc. (ADMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ADMA Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is ADMA Biologics, Inc.'s PE Ratio?

How is the PE Ratio calculated for ADMA Biologics, Inc. (ADMA)?

What is the highest PE Ratio for ADMA Biologics, Inc. (ADMA)?

What is the 3-year average PE Ratio for ADMA Biologics, Inc. (ADMA)?

What is the 5-year average PE Ratio for ADMA Biologics, Inc. (ADMA)?

How does the current PE Ratio for ADMA Biologics, Inc. (ADMA) compare to its historical average?